Wolverine Trading’s Cyclerion Therapeutics CYCN Stock Holding History

Wolverine Trading’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-898	Closed	-$21.6K	–	5585
2021 Q4	$29K	Buy	+898	New	+$42.4K	﹤0.01%	5457

Other funds holding CYCN

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

TCP

Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wolverine Trading's CYCN Position: Q1 2022 in Review

Wolverine Trading sold out of Cyclerion Therapeutics (CYCN) in Q1 2022, closing a stake of 898 shares — an estimated $21.6K sold.

Wolverine Trading first reported a position in CYCN in Q4 2021 and held it in 1 quarter. The position peaked at $29K in Q4 2021. 50 funds tracked by Wall St. Rank hold CYCN as of Q1 2022.

Wolverine Trading reported no remaining Cyclerion Therapeutics position as of Q1 2022 after selling out during the quarter.
Wolverine Trading sold 898 Cyclerion Therapeutics shares in Q1 2022, an estimated $21.6K.
Wolverine Trading first reported a position in Cyclerion Therapeutics in Q4 2021 and held it in 1 quarter.
Wolverine Trading's Cyclerion Therapeutics position peaked at $29K in Q4 2021.
50 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2022.

Based on Wolverine Trading's 13F filing for Q1 2022, filed 16 May 2022.